TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two-Part Pilot Study of Dosing, Safety and Efficacy of Varenicline Initiated During an Acute Smoke-free Hospitalization and Continued Post-Hospitalization
Brief Summary: This Investigator Initiated Research Award (IIR Award #WS981308) is a two-part pilot study that aims to examine acceptability and feasibility of varenicline use during an acute (72-hr) smoke-free hospitalization (Part 1) and 4-weeks post-hospitalization (Part 2).


Options:
A: Arm Label: E-Cigarette; Type: EXPERIMENTAL; Interventions: Behavioral: E-cigarette | Arm Label: Assessments only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: E-cigarette; Assigned to Arm(s): E-Cigarette
B: Arm Label: Order 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 2; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 3; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 4; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Intervention Type: DRUG; Name: Nicotine Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Placebo | Arm Label: Experimental: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Varenicline | Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling; Assigned to Arm(s): Experimental: Varenicline, Placebo Control | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Control | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Experimental: Varenicline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two-Part Pilot Study of Dosing, Safety and Efficacy of Varenicline Initiated During an Acute Smoke-free Hospitalization and Continued Post-Hospitalization
Brief Summary: This Investigator Initiated Research Award (IIR Award #WS981308) is a two-part pilot study that aims to examine acceptability and feasibility of varenicline use during an acute (72-hr) smoke-free hospitalization (Part 1) and 4-weeks post-hospitalization (Part 2).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline
C: Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Placebo | Arm Label: Experimental: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Varenicline | Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling; Assigned to Arm(s): Experimental: Varenicline, Placebo Control | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Control | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Experimental: Varenicline
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two-Part Pilot Study of Dosing, Safety and Efficacy of Varenicline Initiated During an Acute Smoke-free Hospitalization and Continued Post-Hospitalization
Brief Summary: This Investigator Initiated Research Award (IIR Award #WS981308) is a two-part pilot study that aims to examine acceptability and feasibility of varenicline use during an acute (72-hr) smoke-free hospitalization (Part 1) and 4-weeks post-hospitalization (Part 2).


Options:
A: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: bupropion SR, Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Arm Label: II; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: nicotine replacement therapy; Assigned to Arm(s): I, II
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2
C: Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Placebo | Arm Label: Experimental: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Varenicline | Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling; Assigned to Arm(s): Experimental: Varenicline, Placebo Control | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Control | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Experimental: Varenicline
D: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two-Part Pilot Study of Dosing, Safety and Efficacy of Varenicline Initiated During an Acute Smoke-free Hospitalization and Continued Post-Hospitalization
Brief Summary: This Investigator Initiated Research Award (IIR Award #WS981308) is a two-part pilot study that aims to examine acceptability and feasibility of varenicline use during an acute (72-hr) smoke-free hospitalization (Part 1) and 4-weeks post-hospitalization (Part 2).


Options:
A: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: bupropion SR, Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Arm Label: II; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: nicotine replacement therapy; Assigned to Arm(s): I, II
B: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Placebo | Arm Label: Experimental: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Varenicline | Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling; Assigned to Arm(s): Experimental: Varenicline, Placebo Control | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Control | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Experimental: Varenicline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Walnuts on Endothelial Function in Overweight Adults With at Least One Factor of Metabolic Syndrome: A Randomized, Controlled, Cross-Over Trial
Brief Summary: The purpose of this study is to examine the effects of walnut consumption on endothelial function and lipid markers in overweight patients with at least one factor of metabolic syndrome as compared to the control group.


Options:
A: Arm Label: Control diet; Type: ACTIVE_COMPARATOR; Interventions: Other: control diet | Arm Label: Pistachio diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Pistachios | Intervention Type: DIETARY_SUPPLEMENT; Name: Pistachios; Assigned to Arm(s): Pistachio diet | Intervention Type: OTHER; Name: control diet; Assigned to Arm(s): Control diet
B: Intervention Type: DIETARY_SUPPLEMENT; Name: Peanuts and peanut butter; Assigned to Arm(s): N/A
C: Arm Label: Walnut Supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Walnut Supplementation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: No walnut supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnut Supplementation; Assigned to Arm(s): Walnut Supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: No walnut supplementation; Assigned to Arm(s): 2
D: Intervention Type: BEHAVIORAL; Name: Intensive dietary advice; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Fortified Dietary Supplement for Pregnant Women on Maternal and Newborn Outcomes in Kampong Chhnang Province, Cambodia
Brief Summary: The study will evaluate the effects of a nutrition supplement for pregnant women on birth weight and other outcomes. The hypothesis is pregnant women who consume a daily fortified food supplement will produce babies with a higher mean birth weight than those who do not.


Options:
A: Arm Label: Dietary supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Corn Soya Blend+ | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Corn Soya Blend+; Assigned to Arm(s): Dietary supplement
B: Intervention Type: DRUG; Name: NaFeEDTA, Electrolytic Iron; Assigned to Arm(s): N/A
C: Arm Label: Maize porridge with Amaranth; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Maize and Amaranth | Arm Label: Maize flour with multiple micronutrients; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Maize and Amaranth | Arm Label: Maize Porridge; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maize and Amaranth | Intervention Type: DIETARY_SUPPLEMENT; Name: Maize and Amaranth; Assigned to Arm(s): Maize Porridge, Maize flour with multiple micronutrients, Maize porridge with Amaranth
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Lyophilized meat | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Intervention Type: OTHER; Name: Lyophilized meat; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Fortified Dietary Supplement for Pregnant Women on Maternal and Newborn Outcomes in Kampong Chhnang Province, Cambodia
Brief Summary: The study will evaluate the effects of a nutrition supplement for pregnant women on birth weight and other outcomes. The hypothesis is pregnant women who consume a daily fortified food supplement will produce babies with a higher mean birth weight than those who do not.


Options:
A: Arm Label: corn-soy-blend; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: corn-soy blend, Dietary Supplement: iron, Dietary Supplement: folic acid | Arm Label: corn-soy-blend + multiple micronutrients; Type: EXPERIMENTAL; Interventions: Dietary Supplement: corn-soy blend, Dietary Supplement: UNIMMAP | Arm Label: ready-to-use supplementary food; Type: EXPERIMENTAL; Interventions: Dietary Supplement: ready-to-use supplementary food | Intervention Type: DIETARY_SUPPLEMENT; Name: ready-to-use supplementary food; Assigned to Arm(s): ready-to-use supplementary food | Intervention Type: DIETARY_SUPPLEMENT; Name: corn-soy blend; Assigned to Arm(s): corn-soy-blend, corn-soy-blend + multiple micronutrients | Intervention Type: DIETARY_SUPPLEMENT; Name: iron; Assigned to Arm(s): corn-soy-blend | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): corn-soy-blend | Intervention Type: DIETARY_SUPPLEMENT; Name: UNIMMAP; Assigned to Arm(s): corn-soy-blend + multiple micronutrients
B: Arm Label: Dietary supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Corn Soya Blend+ | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Corn Soya Blend+; Assigned to Arm(s): Dietary supplement
C: Arm Label: Folic acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Arm Label: L-5-MTHF; Type: EXPERIMENTAL; Interventions: Dietary Supplement: L-5-MTHF | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: L-5-MTHF; Assigned to Arm(s): L-5-MTHF | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Folate; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Fortified Dietary Supplement for Pregnant Women on Maternal and Newborn Outcomes in Kampong Chhnang Province, Cambodia
Brief Summary: The study will evaluate the effects of a nutrition supplement for pregnant women on birth weight and other outcomes. The hypothesis is pregnant women who consume a daily fortified food supplement will produce babies with a higher mean birth weight than those who do not.


Options:
A: Arm Label: Study product containing milk proteins; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Yogurt-like snacks | Arm Label: Study product containing probiotics; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Yogurt-like snacks | Arm Label: Control product; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Yogurt-like snacks | Intervention Type: DIETARY_SUPPLEMENT; Name: Yogurt-like snacks; Assigned to Arm(s): Control product, Study product containing milk proteins, Study product containing probiotics
B: Arm Label: Dietary supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Corn Soya Blend+ | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Corn Soya Blend+; Assigned to Arm(s): Dietary supplement
C: Arm Label: triple fortified extruded rice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Triple fortified extruded tice (Fe, Zn and vitamin A) | Arm Label: regular meal; Type: OTHER; Interventions: Dietary Supplement: Triple fortified extruded tice (Fe, Zn and vitamin A) | Intervention Type: DIETARY_SUPPLEMENT; Name: Triple fortified extruded tice (Fe, Zn and vitamin A); Assigned to Arm(s): regular meal, triple fortified extruded rice
D: Arm Label: no school meal; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: normal school meal; Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: cold extruded fortified rice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Fortified rice cold extruded kernel | Arm Label: warm extrusion; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fortified rice warm extruded kernel | Arm Label: hot extruded; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fortiified rice hot extruded kernel | Intervention Type: DIETARY_SUPPLEMENT; Name: Fortified rice cold extruded kernel; Assigned to Arm(s): cold extruded fortified rice | Intervention Type: DIETARY_SUPPLEMENT; Name: fortified rice warm extruded kernel; Assigned to Arm(s): warm extrusion | Intervention Type: DIETARY_SUPPLEMENT; Name: fortiified rice hot extruded kernel; Assigned to Arm(s): hot extruded

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomised Study of Nasal Oxygen Treatment for Pain Relief During Percutaneous Coronary Interventions
Brief Summary: Nasal oxygen is widely used as pain relief against ischemic pain during Percutaneous Coronary Intervention (PCI). However, to our knowledge no randomised clinical trials have tested this. In contrast, oxygen causes coronary artery vasoconstriction in man. Furthermore, a recent Cochrane meta-analysis has shown no evidence of beneficial effect of oxygen for patients with acute myocardial infarction (with normal blood saturation. The investigators therefore wanted to examine if oxygen reduces ischemic pain during PCI for stable angina or NSTEMI.


Options:
A: Arm Label: Nasal oxygen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nasal oxygen | Arm Label: Nasal Air; Type: PLACEBO_COMPARATOR; Interventions: Drug: Regular nasal air | Intervention Type: DRUG; Name: Nasal oxygen; Assigned to Arm(s): Nasal oxygen | Intervention Type: DRUG; Name: Regular nasal air; Assigned to Arm(s): Nasal Air
B: Arm Label: normoxia and isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: oxygen and saline | Arm Label: normoxia and 3% hypertonic saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxygen and saline | Arm Label: hyperoxia and isotonic saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxygen and saline | Arm Label: hyperoxia and 3% hypertonic saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxygen and saline | Intervention Type: DRUG; Name: oxygen and saline; Assigned to Arm(s): hyperoxia and 3% hypertonic saline, hyperoxia and isotonic saline, normoxia and 3% hypertonic saline, normoxia and isotonic saline
C: Arm Label: Liberal Oxygenation (LO) group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Modulation of Inspired Fraction of Oxygen (FiO2) | Arm Label: Conservative Oxygenation (CO) group; Type: EXPERIMENTAL; Interventions: Drug: Modulation of Inspired Fraction of Oxygen (FiO2) | Intervention Type: DRUG; Name: Modulation of Inspired Fraction of Oxygen (FiO2); Assigned to Arm(s): Conservative Oxygenation (CO) group, Liberal Oxygenation (LO) group
D: Arm Label: No oxygen; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Oxygen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): Oxygen

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomised Study of Nasal Oxygen Treatment for Pain Relief During Percutaneous Coronary Interventions
Brief Summary: Nasal oxygen is widely used as pain relief against ischemic pain during Percutaneous Coronary Intervention (PCI). However, to our knowledge no randomised clinical trials have tested this. In contrast, oxygen causes coronary artery vasoconstriction in man. Furthermore, a recent Cochrane meta-analysis has shown no evidence of beneficial effect of oxygen for patients with acute myocardial infarction (with normal blood saturation. The investigators therefore wanted to examine if oxygen reduces ischemic pain during PCI for stable angina or NSTEMI.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: AO Therapy (aqueous oxygen) | Intervention Type: DEVICE; Name: AO Therapy (aqueous oxygen); Assigned to Arm(s): 2
B: Arm Label: Oxygen therapy; Type: OTHER; Interventions: Other: Oxygen therapy | Arm Label: No oxygen therapy; Type: OTHER; Interventions: Other: No oxygen therapy | Intervention Type: OTHER; Name: Oxygen therapy; Assigned to Arm(s): Oxygen therapy | Intervention Type: OTHER; Name: No oxygen therapy; Assigned to Arm(s): No oxygen therapy
C: Arm Label: Nasal oxygen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nasal oxygen | Arm Label: Nasal Air; Type: PLACEBO_COMPARATOR; Interventions: Drug: Regular nasal air | Intervention Type: DRUG; Name: Nasal oxygen; Assigned to Arm(s): Nasal oxygen | Intervention Type: DRUG; Name: Regular nasal air; Assigned to Arm(s): Nasal Air
D: Arm Label: No oxygen; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Oxygen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): Oxygen

Answer: C